Nelitolimod - TriSalus Life Sciences
Alternative Names: ISS-ODN SD-101; SD-101; SD101-DynavaxLatest Information Update: 29 Jan 2024
At a glance
- Originator Dynavax Technologies
- Developer Bristol-Myers Squibb; Dynavax Technologies; Merck & Co; National Cancer Institute (USA); Stanford University School of Medicine; TriSalus Life Sciences; University of California, Davis
- Class Antineoplastics; Antivirals; Immunotherapies; Oligodeoxyribonucleotides
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II B-cell lymphoma; Cholangiocarcinoma; Follicular lymphoma; Head and neck cancer; Liver cancer; Lymphoma; Malignant melanoma
- Phase I Pancreatic cancer; Uveal melanoma
- Preclinical Colorectal cancer
- No development reported Haematological malignancies; Hepatitis C; Solid tumours
Most Recent Events
- 22 Jan 2024 Haystack Oncology and TriSalus Life Sciences agree to co-develop Nelitolimod for Liver cancer, Cholangiocarcinoma and Pancreatic-cancer
- 04 Nov 2023 Efficacy and adverse events data from phase-I PERIO-01 trial in Uveal melanoma released by TriSalus Life Sciences
- 03 Nov 2023 Pharmacodynamics and adverse events data from a phase I/Ib PERIO-03 trial in Pancreatic cancer released by TriSalus Life Sciences